3 stocks set to soar after today’s news flow?

Should you pile into these three stocks right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has announced an agreement today with Verily Life Sciences that will see the two companies work together to form Galvani Bioelectronics. The partnership will enable GlaxoSmithKline and Verily (formerly Google Life Sciences) to further the research, development and commercialisation of bioelectronics medicines. GlaxoSmithKline will be the majority stakeholder in the partnership with a 55% stake.

The total investment in Galvani over the next seven years could be as much as £540m and the deal represents an important step forward in GlaxoSmithKline’s bioelectronics research. This should help to further diversity its business model, with its appeal for investors seeking out a resilient, robust and relatively consistent healthcare company remaining high at a time when the outlook for the wider index is highly uncertain.

Although GlaxoSmithKline has risen in value by 24% since the turn of the year, it still yields 4.7%. This not only indicates that it remains a top-notch income play, but also shows that further share price gains could lie ahead – especially with sterling being weak and providing a boost to the company’s bottom line.

Profitable but pricey?

Also reporting today was Fidessa (LSE: FDSA), with the information solutions company’s first half sales rising by 4% (constant currency). In fact, Fidessa’s top line grew across all of its business lines and regions and with 63% of its total revenue being derived from outside of Europe, the potential challenges that may come to the fore in the UK and EU may not dampen Fidessa’s operating performance in future.

Fidessa’s revenue is also made up of 86% recurring revenue, which provides it with relatively high consistency and resilience. And with strong cash generation, Fidessa has been able to increase dividends by 9% in the first half of the year. This puts it on a yield of 3.4% and with its bottom line due to rise by 5% in each of the next two years, further growth in shareholder payouts could be on the horizon.

However, due to Fidessa having a price-to-earnings (P/E) ratio of over 30, now may not be the right time to buy it. Certainly, it may perform well as a business, but for investors there could be better opportunities available elsewhere.

Growth ahead but losses for now

Meanwhile, life sciences and animal care market specialist Avacta (LSE: AVTC) has today released a pre-close trading update prior to the release of its full-year results. Revenues for the year have increased by around 19%, which is in line with market expectations. Although losses almost doubled to £4.6m, this was at least partly due to a change in accounting policy. And with Avacta making strong progress in the development of its Affimer affinity purification systems, its shares could offer improved performance following their 36% fall since the start of the year.

Looking ahead, Avacta expects to continue to grow the pipeline of its Affimer technology evaluations, many of which are now on-going. It anticipates that this will ultimately deliver a flow of ‘Affimer powered’ products to positively catalyse its long-term growth. As such, it has long-term potential, but with it being lossmaking and a relatively small entity, there may be better risk/reward opportunities available elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Fidessa. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »